Key Points
- Director Glenn Nussdorf sold 200,000 shares on Dec. 16 at an average price of $5.14 for proceeds of $1.028M, trimming his stake by 7.23% to 2,565,591 shares.
- Organogenesis beat Q3 estimates (EPS $0.18 vs. $0.07 consensus; revenue $150.86M vs. $134.10M) but still showed a negative net margin (-1.30%) and analysts expect -$0.07 EPS for the fiscal year.
- Shares jumped about 9.5% (opening at $5.77); the company has a market cap of ~$732.3M, a negative PE (~-48.1), and a consensus analyst rating of Hold with an $8 price target.
Organogenesis (NASDAQ:ORGO - Get Free Report) Director Glenn Nussdorf sold 200,000 shares of the company's stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $5.14, for a total value of $1,028,000.00. Following the transaction, the director directly owned 2,565,591 shares in the company, valued at $13,187,137.74. The trade was a 7.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Organogenesis Trading Up 9.5%
Shares of NASDAQ ORGO opened at $5.77 on Friday. The company has a current ratio of 3.32, a quick ratio of 2.88 and a debt-to-equity ratio of 0.01. Organogenesis has a one year low of $2.61 and a one year high of $7.08. The business has a 50-day moving average price of $4.85 and a two-hundred day moving average price of $4.49. The firm has a market capitalization of $732.27 million, a PE ratio of -48.08 and a beta of 1.47.
Organogenesis (NASDAQ:ORGO - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported $0.18 earnings per share for the quarter, beating analysts' consensus estimates of $0.07 by $0.11. The company had revenue of $150.86 million for the quarter, compared to the consensus estimate of $134.10 million. Organogenesis had a positive return on equity of 4.01% and a negative net margin of 1.30%. As a group, analysts predict that Organogenesis will post -0.07 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Organogenesis
Large investors have recently bought and sold shares of the business. Trexquant Investment LP bought a new stake in shares of Organogenesis during the 1st quarter worth about $516,000. Assenagon Asset Management S.A. lifted its holdings in Organogenesis by 748.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 2,857,904 shares of the company's stock worth $10,460,000 after purchasing an additional 2,520,941 shares during the last quarter. Vanguard Group Inc. boosted its position in Organogenesis by 23.4% during the first quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company's stock worth $19,144,000 after purchasing an additional 841,618 shares during the period. American Century Companies Inc. grew its holdings in Organogenesis by 32.7% during the first quarter. American Century Companies Inc. now owns 131,220 shares of the company's stock valued at $567,000 after purchasing an additional 32,328 shares during the last quarter. Finally, Driehaus Capital Management LLC bought a new position in shares of Organogenesis in the first quarter valued at approximately $7,756,000. 49.57% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of research firms have issued reports on ORGO. Wall Street Zen upgraded shares of Organogenesis from a "hold" rating to a "strong-buy" rating in a research report on Saturday, November 8th. BTIG Research reissued a "buy" rating and set a $9.00 price objective on shares of Organogenesis in a research report on Monday. Finally, Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Organogenesis in a research report on Monday. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $8.00.
View Our Latest Analysis on Organogenesis
Organogenesis Company Profile
(
Get Free Report)
Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
